BioMarin Pharmaceuticals
BMRN
580 hedge funds and large institutions have $18.9B invested in BioMarin Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 88 funds opening new positions, 199 increasing their positions, 205 reducing their positions, and 48 closing their positions.
83% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 48
58% more call options, than puts
Call options by funds: $185M | Put options by funds: $117M
21% more capital invested
Capital invested by funds: $15.6B → $18.9B (+$3.24B)
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
5% more funds holding
Funds holding: 551 → 580 (+29)
3% less repeat investments, than reductions
Existing positions increased: 199 | Existing positions reduced: 205
2.06% less ownership
Funds ownership: 100.47% → 98.41% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$134M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
+$81.5M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$67.1M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$66.7M |
| 5 |
Bank of New York Mellon
New York
|
+$52.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$410M |
| 2 |
Millennium Management
New York
|
-$102M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$98.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$81.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$75.6M |
BMRN Hedge Fund Activity: Q4 2022 in Review
580 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2022, worth a combined $18.9B — up 21% from $15.6B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new BMRN positions and 48 closed out — a net gain of 40 holders — while 199 added to existing stakes and 205 trimmed.
The largest buyer was Invesco, adding an estimated $134M. The largest seller was Janus Henderson Group, cutting an estimated $410M.
- 580 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2022, up from 551 in Q3 2022.
- Funds reported $18.9B of BioMarin Pharmaceuticals stock for Q4 2022, up 21% quarter-over-quarter.
- 88 funds opened new BioMarin Pharmaceuticals positions in Q4 2022 and 48 closed out, a net change of +40 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2022 was Invesco, an estimated $134M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2022 was Janus Henderson Group, an estimated $410M sold.
Based on aggregated 13F filings for Q4 2022.